Efficacy/Safety of a Fixed-Dose Amlodipine/Olmesartan Medoxomil-Based Treatment Regimen in Hypertensive Blacks and Non-Blacks With Uncontrolled BP on Prior Antihypertensive Monotherapy

7Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this secondary analysis of a dose-titration study of patients with hypertension uncontrolled on prior monotherapy, blacks (n=234) and non-blacks (n=765) were switched to amlodipine (AML)/olmesartan medoxomil (OM) 5/20 mg, with uptitration every 4 weeks to AML/OM 5/40 mg and then AML/OM 10/40 mg to achieve a seated cuff blood pressure (SeBP) of <120/70 mm Hg. Hydrochlorothiazide 12.5 and 25 mg could be added if SeBP was ≥125/75 mm Hg. The cumulative proportions of patients achieving systolic SeBP <140 mm Hg (<130 mm Hg if diabetic) at 12 weeks were 71.6% for blacks and 77.2% for non-blacks. Mean SeBP change from baseline in blacks (mean baseline BP: 153.0/93.7 mm Hg) ranged from -11.7/-6.1 mm Hg for AML/OM 5/20 mg to -23.6/-12.9 mm Hg for AML/OM 10/40 mg +hydrochlorothiazide 25 mg (all P

Cite

CITATION STYLE

APA

Nesbitt, S., Shojaee, A., & Maa, J. F. (2013). Efficacy/Safety of a Fixed-Dose Amlodipine/Olmesartan Medoxomil-Based Treatment Regimen in Hypertensive Blacks and Non-Blacks With Uncontrolled BP on Prior Antihypertensive Monotherapy. Journal of Clinical Hypertension, 15(4), 247–253. https://doi.org/10.1111/jch.12060

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free